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ABSTRACT (260 word limit; currently 262 words) 
Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying advanced 
fibrosis due to nonalcoholic steatohepatitis (NASH). We analyzed screening data from two phase 
3 trials of selonsertib to assess the ability of NITs to discriminate advanced fibrosis. Centrally 
read biopsies from the STELLAR studies, which enrolled patients with bridging fibrosis and 
compensated cirrhosis, were staged according to the NASH Clinical Research Network (CRN) 
classification. We explored associations between fibrosis stage and NITs, including the NAFLD 
fibrosis score (NFS), Fibrosis-4 (FIB-4) index, Enhanced Liver Fibrosis (ELF) test, and liver 
stiffness by vibration controlled transient elastography (LS by VCTE). The performance of these 
tests to discriminate advanced fibrosis, either alone or in simultaneous and sequential 
combinations, were evaluated using AUROCs with 5-fold cross-validation repeated 100 times. 
Of the 4404 patients screened for these trials, 3202 had evaluable biopsy data: 940 (29%) with 
F0-F2 and 2262 (71%) with F3-F4 fibrosis. Significant differences between median values of 
NITs for patients with F0-F2 vs F3-F4 fibrosis were observed: -0.972 vs 0.318 for NFS, 1.18 vs 
2.20 for FIB-4, 9.22 vs 10.39 for ELF, and 8.8 vs 16.5 kPa for LS by VCTE (all p<0.001). 
AUROCs ranged from 0.75-0.80 to discriminate advanced fibrosis. FIB-4 followed by LS by 
VCTE or ELF test in those with indeterminate values (FIB-4 between 1.3 and 2.67) maintained 
acceptable performance while reducing the rate of indeterminate results. Conclusions: Amongst 
patients being considered for enrolment into clinical trials, NITs alone or in combination can 
reduce the need for liver biopsy to discriminate advanced fibrosis due to NASH. The predictive 
value of these tests for general screening will require confirmation in a real-world population 
with a lower prevalence of advanced fibrosis.   
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INTRODUCTION 
In the United States, nonalcoholic fatty liver disease (NAFLD) is currently the most common 
etiology of liver disease and a leading indication for liver transplantation.1-4 Patients with 
nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD characterized by hepatic 
inflammation and hepatocellular injury, are at greatest risk of progressive fibrosis. Hepatic 
fibrosis is the only independent predictor of clinical disease progression; those with advanced 
fibrosis are at the highest risk of developing decompensated liver disease and/or hepatocellular 
carcinoma which may lead to liver transplantation or death.5-7 The burden of advanced fibrosis 
due to NASH is projected to further increase in coming decades as a consequence of the rising 
prevalence of obesity.8 Given these findings, significant effort has gone into the search for 
pharmacologic treatments for NASH. Experimental drugs directed at a number of therapeutic 
targets are in development and promising preliminary results have been reported.9-11 However, 
even the most effective treatment will not be able to address this large unmet medical need 
without a practical method to identify patients most in need of treatment, i.e., those with 
advanced fibrosis who are at the highest risk of clinical disease progression. Such a method 
would have the additional benefit of reducing unnecessary drug exposure and costs in patients 
least likely to benefit from therapy. While liver biopsy remains the reference standard for staging 
liver fibrosis,12,13 it is costly, invasive, often painful and carries a small but important risk of 
serious complications including bleeding, injury to other organs, and, rarely, death.14 Moreover, 
because the fibrosis in NASH is heterogeneous, sampling error often leads to diagnostic and 
staging misclassification.15 Additionally, there is variability in interpretation of liver biopsy 
results with even highly skilled and trained pathologists showing interobserver concordance rates 
of less than 80%.16 A final drawback of liver biopsy is that it is not suitable for large populations 
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given that many patients are understandably reluctant to undergo the procedure. Even a low risk 
of serious complications from liver biopsy would translate into clinically meaningful numbers of 
complications if the population undergoing the procedure was sufficiently large. Moreover, the 
number of liver biopsies that can actually be performed is limited by the lack of providers, who 
would be unable to meet the potential demand. All these factors contribute to the observation that 
the majority of patients with a suspected diagnosis of NASH have never undergone a liver 
biopsy.   
The ideal test to discriminate advanced liver fibrosis due to NASH would be noninvasive, widely 
available, affordable, accurate, and reproducible. A number of existing NITs, including 
composite clinical scores, serum markers, and assessment of liver stiffness by vibration 
controlled transient elastography (LS by VCTE) have demonstrated a number of these criteria for 
evaluation of advanced fibrosis. The objectives of this analysis were to assess the performance of 
several widely available NITs in identifying patients with advanced fibrosis due to NASH in a 
population at high risk for advanced disease participating in a clinical trial.    
METHODS 
Analysis Population 
We analyzed screening data from two phase 3 studies of the ASK1 inhibitor selonsertib in 
patients with NASH. These global studies, which enrolled patients from 26 countries in North 
and South America, Europe, Australia, New Zealand, and Asia, were identical in design except 
for the populations enrolled: the STELLAR-3 trial (NCT03053050) included patients with 
bridging fibrosis (F3), and the STELLAR-4 trial (NCT03053063) included patients with 
compensated cirrhosis (F4). Briefly, the studies were designed to enroll patients 18 to 70 years of 
age with a histologic diagnosis of NASH. A historical liver biopsy was acceptable provided that 
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it was performed within 6 months of screening for STELLAR-3 and 12 months of screening for 
STELLAR-4. Patients with liver disease of other etiologies (including alcoholic liver disease, 
hepatitis B, hepatitis C, and autoimmune disorders), or a history of liver transplantation, hepatic 
decompensation, or hepatocellular carcinoma were excluded. The full eligibility criteria for both 
studies are provided in the Supplementary Appendix. 
Assessments 
Liver biopsy specimens were collected at screening from patients who had not had a liver biopsy 
performed within the previous 6 months for STELLAR-3 and within the previous 12 months for 
STELLAR-4. All biopsy samples were read by a central reader (ZG) for eligibility, including an 
assessment of the adequacy of the specimen, the fibrosis stage (according to the NASH Clinical 
Research Network (CRN) classification), and a determination that the biopsy was consistent with 
NASH (NAFLD Activity Score [NAS] ≥3 with ≥grade 1 for each of steatosis, hepatocellular 
ballooning, and lobular inflammation). Fasting blood samples were collected at screening for 
clinical laboratory values, including ALT, AST, alkaline phosphatase (ALP), GGT, bilirubin, 
albumin, platelets, and international normalized ratio (INR).  
This analysis focused on four noninvasive markers of fibrosis: FIB-4, NAFLD Fibrosis Score 
(NFS), the ELF test, and LS by VCTE. All biochemical parameters were measured by the 
Covance central laboratory; ELF analytes were measured using the Siemens Centaur platform. 
The formulae for these markers are presented in Table 1. Because the assessment of LS by 
VCTE was optional, the cohort of patients with VCTE data was a subset of the total analysis 
population (1765 of 3202) that was skewed towards those who qualified for enrollment and were 
therefore more likely to have advanced fibrosis (see Supplemental Table 1).   
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Statistical Analyses 
The performance of NITs to discriminate advanced (F3–4) fibrosis was evaluated using areas 
under the receiver operating characteristic curve (AUROCs) with 5-fold cross-validation 
repeated 100 times; thresholds of single tests for F3–4 fibrosis were selected based on the 
literature (Table 1).17-20 We evaluated approaches using a single test with one threshold, a single 
test with two thresholds, and two tests in simultaneous and sequential combinations.21 In the 
simultaneous 2-test approach, we performed both tests simultaneously in all patients. In the 
sequential 2-test approach, we performed the first test in all patients, and performed the second 
test only in those patients with indeterminate results from the first test. In sensitivity analyses, 
the impact of biopsy quality (length and number of portal triads), obesity (BMI < vs. ≥30 kg/m2), 
and reliability of LS by VCTE (IQR/median values < vs. ≥30%) on AUROCs were evaluated. 
Since the accuracy of these tests may vary according to age, particularly NFS and FIB-4 which 
include age as a component, we also evaluated diagnostic performance in age strata (18-39, 40-
64, and ≥65 years).22 
For deriving novel, optimal thresholds from the STELLAR studies, the cohort was divided 
(80/20%) into evaluation/validation sets; the evaluation set was further stratified 250 times into 
training and test sets (66/33%), with balanced NASH CRN fibrosis stage and diabetes status, for 
the purpose of variability evaluation. Optimal thresholds of the single tests were obtained by 
maximizing specificity given sensitivity ≥85%, or vice versa, within each training set and then 
averaging over 250 training sets for final estimates. The performance metrics of the novel 
thresholds were evaluated in the evaluation and validation sets; thresholds from the literature 
were also examined. The indeterminate zone (assumed to be later diagnosed using biopsy with 
100% accuracy) was incorporated in the calculations of the performance metrics. 
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RESULTS 
Analysis Population 
A total of 4404 patients were screened for eligibility for these two trials (2273 for STELLAR-3 
and 2194 for STELLAR-4). Of these, 3202 patients had evaluable histology (896 [28%] had 
historical biopsies and 2306 [72%] underwent new biopsies for the study) and are included in 
this analysis (Table 2 and Supplemental Table 2 for the characteristics of the enrolled 
populations). The median (IQR) delay between liver biopsy and noninvasive testing was 34 days 
(-8, 63). Fibrosis stages were as follows: 246 (8%) F0 fibrosis, 276 (9%) F1 fibrosis, 418 (13%) 
F2 fibrosis, 979 (31%) F3 (bridging) fibrosis, and 1283 (40%) F4 (cirrhosis). In total, 0.7% 
(n=15) of the 2306 patients who underwent liver biopsy as part of study procedures had at least 
one serious adverse event related to liver biopsy, including hemorrhage requiring hospitalization 
(Supplemental Table 3). The mean (SD) length of liver biopsy samples was 2.2 cm (1.27) in the 
F0-F2 cohort and 2.3 cm (1.24) in the F3-F4 cohort.  
Values of NFS, FIB-4, ELF, and LS by VCTE increased with increasing fibrosis stage 
(Supplemental Table 4) and median values of all four NITs were significantly greater in 
patients with F3-F4 fibrosis (n=2262) versus those with F0-F2 fibrosis (n=940) (Supplemental 
Figure 1). All four NITs were moderately correlated with fibrosis stage (Spearman ρ: NFS, 0.44; 
FIB-4, 0.51; ELF, 0.53, and LS by VCTE, 0.54; all p<0.0001). 
Single NITs Using a Single Threshold 
We first explored the use of single NITs with a single threshold to discriminate patients with F3-
F4 fibrosis. The AUROCs to discriminate advanced fibrosis were 0.74 for NFS, 0.78 for FIB-4, 
and 0.80 for both ELF and LS by VCTE (Table 3). For each NIT, we evaluated two thresholds 
8 
 
derived from the literature. We generally found that a threshold with a high degree of sensitivity 
had an unacceptably low degree of specificity and vice versa. For example, a threshold of ≤-
1.455 for NFS was able to detect F3-F4 fibrosis with 89% sensitivity, but was only 37% specific. 
The reverse was true for an NFS threshold of ≥0.676, which had a specificity of 89%, but 
sensitivity of only 38%. Sensitivity analyses revealed that biopsy quality, obesity, and reliability 
of LS by VCTE (as defined by VCTE readings IQR </> 30%) did not have a substantial impact 
on the diagnostic performance of the NITs (Supplemental Tables 5 and 6).  
The prevalence of advanced fibrosis increased in the higher age strata (18-39 years: 45% 
[85/190]; 40-64 years: 70% [1599/2285]; ≥65 years: 80% [578/727]; p<0.0001). With respect to 
diagnostic performance of the NITs, in general, the sensitivity increased, and the specificity 
decreased, with rising age. Applying standard non-age adjusted thresholds, NFS performed least 
well in patients ≥65 years (AUROC 0.68 vs. 0.74-0.75 for 18-39 and 40-64 year groups), while 
FIB-4 performed least well in the youngest age group (AUROCs 0.69 for 18-39 years vs. 0.74-
0.78 for 40-64 and ≥65 years) (Supplemental Table 7). Discrimination of LS by VCTE was 
highest in patients age 40-64 years (AUROC 0.82 vs. 0.73-0.74 in other groups). While ELF 
performance was generally more stable across age strata (AUROCs 0.74-0.79), here too 
specificity for F3-4 fibrosis fell below 60% amongst patients ≥65 years.  
Single NITs with Upper and Lower Thresholds 
As no single threshold for any individual NIT adequately balanced sensitivity and specificity, we 
explored the use of single NITs with 2 thresholds (a lower threshold to maximize sensitivity and 
a higher threshold to maximize specificity) to discriminate F3-F4 fibrosis. All patients at or 
below the lower threshold were categorized as not having advanced fibrosis and all patients at or 
above the higher threshold were categorized as having advanced fibrosis. This approach 
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provided moderately high degrees of sensitivity and specificity (Table 4), but was characterized 
by a large proportion of patients in the indeterminate zone between these two thresholds. For 
example, using FIB-4 with a lower threshold of <1.3 and an upper threshold of ≥2.67 provided a 
sensitivity of 82% and specificity of 93%; however, results in 43% of patients were between 
these thresholds precluding classification. Novel thresholds derived from the STELLAR data did 
not significantly improve NIT performance (Supplemental Table 8). 
Simultaneous Combinations of 2 NITs 
In an effort to improve further upon the performance of individual NITs, we explored 
simultaneous and sequential combinations of NITs utilizing two NITs with lower and upper 
thresholds. All patients below both lower thresholds and at or above both upper thresholds were 
classified as not having or having F3-F4 fibrosis, respectively (Table 4). The simultaneous use 
of two NITs resulted in improved sensitivity and specificity compared with a single NIT (≥89% 
and ≥97%, respectively), but predictably increased the proportion of patients who fell in the non-
diagnostic, indeterminate zone. For example, using both NFS and ELF discriminated advanced 
fibrosis with a sensitivity of 94% and a specificity of 99%, but increased the proportion of 
patients with indeterminate results to 77%. 
Sequential Combinations of NITs 
Due to this high rate of indeterminate results with the simultaneous combination approach, we 
explored the use of two NITs in sequential combination for discriminating advanced fibrosis. In 
this approach, patients would first be classified using one NIT with lower and upper thresholds. 
Then a second NIT with two thresholds was used to categorize all those who fell in the 
indeterminate zone with the first NIT. This approach reduced the frequency of indeterminate 
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results to as low as 20% while slightly increasing the rate of misclassification, yet generally 
maintained acceptable sensitivity and specificity (Table 5). As shown with the prior approaches, 
novel thresholds derived from the STELLAR data performed similarly to the existing literature-
based NIT thresholds (Supplemental Table 9). Adding a third NIT (FIB-4 followed by ELF 
then LS by VCTE) further reduced the indeterminate zone to ≤10%, but increased the 
misclassification rate using either literature-based or novel thresholds (Supplemental Table 10). 
 
DISCUSSION 
Testing for the presence of advanced fibrosis is a primary concern when evaluating a patient with 
suspected NASH. As fibrosis is the only independent predictor of associated morbidity and 
mortality, the presence of advanced fibrosis, including cirrhosis, alters clinical management 
including the possible initiation of surveillance for hepatocellular carcinoma, and consideration 
for treatment, including in the context of clinical trials. Given the significant limitations of liver 
biopsy, which include safety concerns, inaccuracy, patient reluctance, and lack of availability, 
there is a large unmet medical need to develop noninvasive methods to identify patients with 
advanced fibrosis. In these large, global phase 3 trials of selonsertib, the rate of serious 
complications from liver biopsy was 0.7%, consistent with the published rate.14 Several NITs—
chosen for their widespread availability and common use in clinical practice—demonstrated 
acceptable diagnostic performance for the discrimination of advanced fibrosis, particularly when 
compared to the imperfect reference standard of liver biopsy. In this population of patients at 
high risk for advanced fibrosis due to NASH, NITs used individually—NFS, FIB-4, ELF, or LS 
by VCTE—yielded AUROCs ranging from 0.74 to 0.80. Similar findings were observed for 
discrimination of cirrhosis (F4) (Supplemental Tables 11-13). While the observed performance 
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is modest, given the inaccuracy of liver biopsy as reference standard, the maximum AUROC 
attainable to discriminate advanced fibrosis is likely 0.90 or lower.23 Novel thresholds of NITs 
derived from the STELLAR studies were generally consistent with literature-based thresholds 
confirming that the generally accepted, published thresholds for advanced fibrosis remain 
optimal. Sensitivity analyses revealed that obesity and reliability of LS by VCTE did not have a 
substantial impact on NIT performance; however, some variability was observed by age 
category, as previously described.22 
While the overall discrimination of advanced fibrosis was acceptable, there was no single 
threshold that could optimally balance sensitivity and specificity. Consistent with clinical 
practice, a lower threshold that maximizes sensitivity and a higher threshold for specificity were 
required. The use of these two thresholds, however, introduced a grey zone of indeterminate, 
non-diagnostic results which occurred in up to 51% of patients when using a single NIT and up 
to 77% when two NITs were combined simultaneously, thus limiting the clinical utility. When 
NITs were used in sequential combination, sensitivity and specificity were maintained and the 
rate of non-diagnostic results was reduced to ~20%. Overall, the misclassification rate of the 
NITs was approximately 20% and primarily included NIT false negatives, i.e., those with 
advanced fibrosis on biopsy but not meeting the NIT threshold(s). Less than 11% of those 
misclassified were NIT false positives and would have been identified as advanced fibrosis by 
the NIT but not confirmed on liver histology. These data suggest that use of NITs with current 
literature-based thresholds to identify patients with advanced fibrosis would not result in 
substantial over-treatment of patients with early or no fibrosis. Interestingly, in a comparison of 
baseline characteristics of false positive and negative cases according to the two sequential 
algorithms with the remainder of the cohort (Supplemental Tables 14 and 15), false positives 
12 
 
had characteristics more aligned with those of patients with F3-F4 fibrosis than those with F0-F2 
fibrosis on biopsy (e.g. age, liver biochemistry, bilirubin, MELD, platelets, bile acids, NFS, 
FibroSure/FibroTest and APRI). Conversely, false negatives had features more similar to those 
of patients with F0-F2 versus F3-F4 fibrosis on biopsy. These data suggest that at least part of 
the observed discordances could be due to inaccuracy of liver biopsy.  
Our findings add to accumulating literature that combinations of NITs in sequential algorithms 
can accurately detect advanced fibrosis while eliminating the risks associated with biopsy and 
reducing costs by minimizing unnecessary testing.24 Recent reports describe referral pathways 
similar to ours involving algorithms that begin with an initial screen by primary care providers 
using a simple test based on routinely collected laboratory values, such as FIB-4.25,26 Patients 
judged at high risk on the basis of this result could be referred to a hepatologist for follow-up 
with more specialized and less widely available tests, such as ELF or LS by VCTE. While our 
focus was primarily on NFS, FIB-4, ELF, and VCTE, substantial additional literature is available 
to support the use of other NITs including FibroSure/FibroTest, the CA index, and algorithms 
incorporating VCTE and AST.27-31   
The strengths of our study included the large, international population of patients enrolled. 
Additionally, all liver biopsies were read by a single, experienced pathologist, and all of the NITs 
were performed according to manufacturer specifications at qualified labs or by qualified 
technicians following a standardized format. Notably, biopsy quality did not affect the AUROCs 
of NITs to discriminate advanced fibrosis. The generalizability of these data is limited by several 
considerations. The most important limitation is that this was not a ‘real world’ cohort of patients 
with NAFLD, but a carefully curated population of patients that a priori were being considered 
for enrolment in a clinical trial for a treatment for advanced fibrosis. While 31% of patients had 
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results of a historical biopsy available prior to screening, excluding these patients actually 
slightly increased the AUROCs of the NITs to discriminate advanced fibrosis (ranging from 
0.76-0.81), suggesting that the performance of these NITs was not affected by the inclusion of 
patients with known F3-F4 fibrosis. The prevalence of advanced fibrosis ranged from 71-84% 
depending on the NIT population (as not all NITs were performed in all patients). This high 
prevalence makes interpretation of the positive and negative predictive values difficult, so that 
the focus should be on sensitivity and specificity which are not affected by prevalence. A recent 
meta-analysis by Xiao and colleagues evaluating the performance of a range of NITs for the 
detection of fibrosis may offer positive and negative predictive values more suitable for a 
screening population.32  
In summary, we have shown that commonly available NITs perform well in identifying patients 
with advanced fibrosis due to NASH. While there is some expected inaccuracy, particularly 
when compared to an imperfect reference standard like liver biopsy, the degree of diagnostic 
inaccuracy that will be acceptable will ultimately depend on the efficacy and safety of new 
treatments. Further validation of these findings in additional cohorts is planned.    
14 
 
ACKNOWLEDGMENTS 
Supported by Gilead Sciences. QMA is a Newcastle NIHR Biomedical Research Center 
investigator.  
Presented in part at the annual meeting of the American Association for the Study of Liver 
Diseases held in San Francisco, CA on November 9-13, 2018. 
We thank the patients and their families, as well as the investigators and site personnel. 
Editorial and writing assistance was provided by David McNeel of Gilead Sciences. 
 
  
15 
 
REFERENCES 
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of 
NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol 
Hepatol 2018;15:11-20.  
2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 
10:686–690. 
3. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. 
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults 
awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-55.  
4. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause 
of liver transplant in women: updated analysis of indications for liver transplant and ethnic and 
gender variances. Am J Gastroenterol 2018,113:1649-1659. 
5. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. 
Hepatology. 2015;61:1547-1554. 
6. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et 
al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients 
with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397. 
7. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality 
by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. 
Hepatology 2017;65:1557–1565. 
8. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of 
nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. 
Hepatology 2018;67:123-133.  
9. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an 
agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of 
nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150:1147-1159. 
16 
 
10. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, 
et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic 
steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 
2015;385:956-965. 
11. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 
inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. 
Hepatology 2018;67:549-559. 
12. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med 
2017;377:756-68. 
13. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis 
and management of nonalcoholic fatty liver disease: practice guidance from the American 
Association for the Study of Liver Diseases. Hepatology 2017:xxx1-88. 
14. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 
2009;49:1017-1044. 
15. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability 
of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906. 
16. Bedossa P, Bioulac-Sage P, Callard P, Chevallier M, Degott C, Deugnier Y, et al. 
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic 
hepatitis C. Hepatology 1994;20:15-20. 
17. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of 
noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin 
Gastroenterol Hepatol 2009;7:1104-12; 6.  
18. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD 
fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. 
Hepatology 2007;45:846-54; 4.  
19. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver 
Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 
2013;59:236-42.  
17 
 
20. Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled 
transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J 
Gastroenterol 2016;111:677-684. 
21. Petta S, Wong VW, Cammà C, Hiriart JB, Wong GL, Vergniol J, et al. Serial combination of 
noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with 
nonalcoholic fatty liver disease. J Hepatol 2017;66:S591. 
22. McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a 
confounding factor for the accurate non-invasive diagnosis of advanced nafld fibrosis. Am J 
Gastroenterol 2017;112:740-751. 
23. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. 
J Hepatol 2009;50:36-41. 
24. Castera L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-
invasive tests are enough. Liver Int 2018;38(Suppl):67-70. 
25. Davyduke T, Abraldes JG, Tandon P, Ma MM. Impact of pre-screening with Fibrosis-4 
index on a referral pathway for patients with suspected NAFLD. Hepatology 
2018;68(Suppl):44A.  
26. Tsochatzis EA, Newsome P. Non-alcoholic fatty liver disease and the interface between 
primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-517. 
27. Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy 
and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan 
in non-alcoholic fatty liver disease. J Hepatol 2016;65:570-578. 
28. Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, et al. Accuracy of non-
invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: 
Multicenter validation study. Hepatol Res 2018;48:1099-1107.  
29. Loomba R, Jain A, Diehl AM, Guy CD, Portenier D, Sudan R, et al. Validation of serum test 
for advanced liver fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol 
Hepatol 2018 [epub ahead of print]. 
18 
 
30. Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, et al. Identification of 
novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by 
data mining. Hepatology. 2016;63:462-473. 
31. Okanoue T, Ebise H, Kai T, Mizuno M, Shima T, Ichihara J, et al. A simple scoring system 
using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic 
steatohepatitis and related fibrosis. J Gastroenterol 2018;53:129-139. 
32. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or 
magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver 
disease: a meta-analysis. Hepatology 2017;66:1486-1501. 
